JFG
ATXS

Jefferies Financial Group’s Astria Therapeutics ATXS Stock Holding History

Jefferies Financial Group’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-50,000
Closed -$384K – 1605
2023
Q4 		$384K Buy
+50,000
New +$276K ﹤0.01% 1310

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jefferies Financial Group's ATXS Position: Q1 2024 in Review

Jefferies Financial Group sold out of Astria Therapeutics (ATXS) in Q1 2024, closing a stake of 50,000 shares — an estimated $384K sold.

Jefferies Financial Group first reported a position in ATXS in Q4 2023 and held it in 1 quarter. The position peaked at $384K in Q4 2023. 102 funds tracked by Wall St. Rank hold ATXS as of Q1 2024.

  • Jefferies Financial Group reported no remaining Astria Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Jefferies Financial Group sold 50,000 Astria Therapeutics shares in Q1 2024, an estimated $384K.
  • Jefferies Financial Group first reported a position in Astria Therapeutics in Q4 2023 and held it in 1 quarter.
  • Jefferies Financial Group's Astria Therapeutics position peaked at $384K in Q4 2023.
  • 102 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2024.

Based on Jefferies Financial Group's 13F filing for Q1 2024, filed 13 May 2024.